Walter Ried
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Walter Ried has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Axel Kramer
University Medicine Greifswald
1 shared publication - Christian Schäfer
Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald , Greifswald
1 shared publication - Claudia Hübner
University of Greifswald
1 shared publication - Florian Wilke
Institut für Hygiene und Umweltmedizin, Ernst-Moritz-Arndt-Universität, Greifswald, Germany
1 shared publication - Franziska Claus
Lehrstuhl für Allgemeine Volkswirtschaftslehre und Finanzwissenschaft, Ernst-Moritz-Arndt-Universität, Greifswald, Germany
1 shared publication - Georg Engel
Universitätsapotheke, Ernst-Moritz-Arndt-Universität, Greifswald, Germany
1 shared publication
Latest Publications
- Open Access
- 23 June 2017
- Published by Walter de Gruyter GmbH in Engineering Management in Production and Services
- Vol. 9 (2) , 8-20
Cross-Border Health Care in the European Union: Evaluation of Different Financing Arrangements
This paper analyses the impact of the financing arrangements for planned cross-border health care within the European Union. A financial arrangement is taken to provide a financial incentive but may also involve payment risks and administrative burden. For the pathways given by the Social Security Regulations (883/2004 and 987/2009) and the EU Directive 2011/24/EU, we investigate how the associated financial arrangements act on providers, patients and on publicly funded health insurance. First, the Regulations can induce cross-border health care that will increase domestic health care expenditure and may threaten national health policy by setting an incentive for patients to go abroad for health care not covered by domestic health insurance. Second, the financial arrangement of the Directive may induce cross-border health care which will lower domestic health care expenditure. However, due to considerable payment risks and administrative burden on both patients and providers, these benefits will not be reaped in full. Moreover, in the presence of national cost containment policies, the Directive may provide an incentive for cross-border health care that is too strong. Finally, due to the requirement to pay upfront, the financial arrangement also suffers from a lack of equity of access to health care provision abroad.
- 23 June 2017
- Published by Walter de Gruyter GmbH in Engineering Management in Production and Services
- Vol. 9 (2) , 8-20
Open AccessCross-Border Health Care in the European Union: Evaluation of Different Financing Arrangements
This paper analyses the impact of the financing arrangements for planned cross-border health care within the European Union. A financial arrangement is taken to provide a financial incentive but may also involve payment risks and administrative burden. For the pathways given by the Social Security Regulations (883/2004 and 987/2009) and the EU Directive 2011/24/EU, we investigate how the associated financial arrangements act on providers, patients and on publicly funded health insurance. First, the Regulations can induce cross-border health care that will increase domestic health care expenditure and may threaten national health policy by setting an incentive for patients to go abroad for health care not covered by domestic health insurance. Second, the financial arrangement of the Directive may induce cross-border health care which will lower domestic health care expenditure. However, due to considerable payment risks and administrative burden on both patients and providers, these benefits will not be reaped in full. Moreover, in the presence of national cost containment policies, the Directive may provide an incentive for cross-border health care that is too strong. Finally, due to the requirement to pay upfront, the financial arrangement also suffers from a lack of equity of access to health care provision abroad.
- 7 April 2016
- Published by Springer Nature
- p. 1-23
Gesundheitsversorgung im ländlichen Raum: Ziele und Indikatoren
- 7 April 2016
- Published by Springer Nature
- p. 1-23
Gesundheitsversorgung im ländlichen Raum: Ziele und Indikatoren
- 1 March 2016
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 24 (1) , 47-49
Gesundheitsversorgung im ländlichen Raum: Ziele, Chancen, Hindernisse
Zusammenfassung: Die demografische Alterung betrifft im ländlichen Raum dünn besiedelte oder strukturschwache Regionen besonders stark. Um die Gesundheitsversorgung der lokalen Bevölkerung zu sichern, ist die aktuelle Versorgungslage im Hinblick auf die Aspekte Bedarf, Angebot und Zugang abzubilden. Auf dieser Grundlage können neue Konzepte entwickelt und angewendet werden, die zur Verbesserung der Gesundheitsversorgung beitragen und damit die mit dem geo-demografischen Wandel verbundenen Chancen realisieren.
- 1 March 2016
- Published by Walter de Gruyter GmbH in Public Health Forum
- Vol. 24 (1) , 47-49
Gesundheitsversorgung im ländlichen Raum: Ziele, Chancen, Hindernisse
Zusammenfassung: Die demografische Alterung betrifft im ländlichen Raum dünn besiedelte oder strukturschwache Regionen besonders stark. Um die Gesundheitsversorgung der lokalen Bevölkerung zu sichern, ist die aktuelle Versorgungslage im Hinblick auf die Aspekte Bedarf, Angebot und Zugang abzubilden. Auf dieser Grundlage können neue Konzepte entwickelt und angewendet werden, die zur Verbesserung der Gesundheitsversorgung beitragen und damit die mit dem geo-demografischen Wandel verbundenen Chancen realisieren.
- Open Access
- 22 October 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-13
Improving hospital hygiene to reduce the impact of multidrug-resistant organisms in health care–a prospective controlled multicenter study
Nosocomial infections are the most common complication during inpatient hospital care. An increasing proportion of these infections are caused by multidrug-resistant organisms (MDROs). This report describes an intervention study which was designed to address the practical problems encountered in trying to avoid and treat infections caused by MDROs. The aim of the HARMONIC (Harmonized Approach to avert Multidrug-resistant Organisms and Nosocomial Infections) study is to provide comprehensive support to hospitals in a defined study area in north-east Germany, to meet statutory requirements. To this end, a multimodal system of hygiene management was implemented in the participating hospitals. HARMONIC is a controlled intervention study conducted in eight acute care hospitals in the ‘Health Region Baltic Sea Coast’ in Germany. The intervention measures include the provision of written recommendations on methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and multi-resistant Gram-negative bacteria (MRGN), supplemented by regional recommendations for antibiotic prescriptions. In addition, there is theoretical and practical training of health care workers (HCWs) in the prevention and handling of MDROs, as well as targeted and critically gauged applications of antibiotics. The main outcomes of the implementation and analysis of the HARMONIC study are: (i) screening rates for MRSA, VRE and MRGN in high-risk patients, (ii) the frequency of MRSA decolonization, (iii) the level of knowledge of HCWs concerning MDROs, and (iv) specific types and amounts of antibiotics used. The data are predominantly obtained by paper-based questionnaires and documentation sheets. A computer-assisted workflow-based documentation system was developed in order to provide support to the participating facilities. The investigation includes three nested studies on risk profiles of MDROs, health-related quality of life, and cost analysis. A six-month follow-up study investigates the quality of life after discharge, the long-term costs of the treatment of infections caused by MDROs, and the sustainability of MRSA eradication. The aim of this study is to implement and evaluate an area-wide harmonized hygiene program to control the nosocomial spreading of MDROs. Comparability between the intervention and control group is ensured by matching the hospitals according to size (number of discharges per year / number of beds) and level of care (standard or maximum). The results of the study may provide important indications for the implementation of regional MDRO management programs.
- 22 October 2015
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 15 (1) , 1-13
Open AccessImproving hospital hygiene to reduce the impact of multidrug-resistant organisms in health care–a prospective controlled multicenter study
Nosocomial infections are the most common complication during inpatient hospital care. An increasing proportion of these infections are caused by multidrug-resistant organisms (MDROs). This report describes an intervention study which was designed to address the practical problems encountered in trying to avoid and treat infections caused by MDROs. The aim of the HARMONIC (Harmonized Approach to avert Multidrug-resistant Organisms and Nosocomial Infections) study is to provide comprehensive support to hospitals in a defined study area in north-east Germany, to meet statutory requirements. To this end, a multimodal system of hygiene management was implemented in the participating hospitals. HARMONIC is a controlled intervention study conducted in eight acute care hospitals in the ‘Health Region Baltic Sea Coast’ in Germany. The intervention measures include the provision of written recommendations on methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and multi-resistant Gram-negative bacteria (MRGN), supplemented by regional recommendations for antibiotic prescriptions. In addition, there is theoretical and practical training of health care workers (HCWs) in the prevention and handling of MDROs, as well as targeted and critically gauged applications of antibiotics. The main outcomes of the implementation and analysis of the HARMONIC study are: (i) screening rates for MRSA, VRE and MRGN in high-risk patients, (ii) the frequency of MRSA decolonization, (iii) the level of knowledge of HCWs concerning MDROs, and (iv) specific types and amounts of antibiotics used. The data are predominantly obtained by paper-based questionnaires and documentation sheets. A computer-assisted workflow-based documentation system was developed in order to provide support to the participating facilities. The investigation includes three nested studies on risk profiles of MDROs, health-related quality of life, and cost analysis. A six-month follow-up study investigates the quality of life after discharge, the long-term costs of the treatment of infections caused by MDROs, and the sustainability of MRSA eradication. The aim of this study is to implement and evaluate an area-wide harmonized hygiene program to control the nosocomial spreading of MDROs. Comparability between the intervention and control group is ensured by matching the hospitals according to size (number of discharges per year / number of beds) and level of care (standard or maximum). The results of the study may provide important indications for the implementation of regional MDRO management programs.
- Open Access
- 15 December 2011
- Published by Georg Thieme Verlag KG
- Vol. 6 (1) , Doc23
On the economic impact of a regional management of multidrug-resistant bacteria.
The increasing number of people who are colonized or infected with multidrug-resistant bacteria imposes a high economic burden on society which includes the negative impact on health status as an intangible cost. An economic analysis leads to the conclusion that currently too little is done to prevent or control infections. The reasons include insufficient incentives for health care providers, a lack of reliable data on both the prevalence and the effects of infection, and a lack of coordination among the different branches of the health care sector. A regional management of multidrugresistant bacteria which does not focus on a single branch but rather on the health care sector overall can achieve a substantial reduction in the number of infected people and of the associated economic cost for society.
- 15 December 2011
- Published by Georg Thieme Verlag KG
- Vol. 6 (1) , Doc23
Open AccessOn the economic impact of a regional management of multidrug-resistant bacteria.
The increasing number of people who are colonized or infected with multidrug-resistant bacteria imposes a high economic burden on society which includes the negative impact on health status as an intangible cost. An economic analysis leads to the conclusion that currently too little is done to prevent or control infections. The reasons include insufficient incentives for health care providers, a lack of reliable data on both the prevalence and the effects of infection, and a lack of coordination among the different branches of the health care sector. A regional management of multidrugresistant bacteria which does not focus on a single branch but rather on the health care sector overall can achieve a substantial reduction in the number of infected people and of the associated economic cost for society.
- Open Access
- 1 December 2008
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 8 (6) , 515-518
Health status and the cost of intensive care unit treatment
- 1 December 2008
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 8 (6) , 515-518
Open AccessHealth status and the cost of intensive care unit treatment
- 1 October 2007
- Published by Walter de Gruyter GmbH in Jahrbücher für Nationalökonomie und Statistik
- Vol. 227 (5-6) , 636-659
Medizinisch-technischer Fortschritt und altersspezifische Gesundheitsausgaben / Medical Progress and Age-specific Expenditure on Health Care
Summary: This paper investigates the impact of population aging, driven by medical progress, upon agespecific expenditure on health care. In a model set up in discrete time, individuals at each age may catch a lethal disease which, upon receiving appropriate medical treatment, nevertheless involves a mortality risk. The incidence of lethal diseases, the associated survival probability conditional upon treatment, and health care expenditure conditional upon health status may all depend on an individual’s history of health status in the past. Medical progress is taken to involve an increase in the survival probability of a specified lethal disease. First, this produces a direct effect on age-specific health care expenditure to the extent that progress affects the cost of treatment of the disease. Second, indirect effects may also arise relating to individuals who, having survived the disease at some prior age, change the structure of individuals alive at current age. Specifically, these “new survivors” may influence age-specific expenditure either through changes in the incidence of lethal diseases or in the associated treatment cost. The sign of an indirect effect crucially depends on health care expenditure for “new survivors” relative to their peers. The analysis yields a number of general results with respect to the impact of medical progress on the age profile of health care expenditure. For example, both compression of morbidity and expansion of morbidity are hypotheses which relate to “new survivors” such that they fail to account for the total effect of progress on age-specific expenditure.
- 1 October 2007
- Published by Walter de Gruyter GmbH in Jahrbücher für Nationalökonomie und Statistik
- Vol. 227 (5-6) , 636-659
Medizinisch-technischer Fortschritt und altersspezifische Gesundheitsausgaben / Medical Progress and Age-specific Expenditure on Health Care
Summary: This paper investigates the impact of population aging, driven by medical progress, upon agespecific expenditure on health care. In a model set up in discrete time, individuals at each age may catch a lethal disease which, upon receiving appropriate medical treatment, nevertheless involves a mortality risk. The incidence of lethal diseases, the associated survival probability conditional upon treatment, and health care expenditure conditional upon health status may all depend on an individual’s history of health status in the past. Medical progress is taken to involve an increase in the survival probability of a specified lethal disease. First, this produces a direct effect on age-specific health care expenditure to the extent that progress affects the cost of treatment of the disease. Second, indirect effects may also arise relating to individuals who, having survived the disease at some prior age, change the structure of individuals alive at current age. Specifically, these “new survivors” may influence age-specific expenditure either through changes in the incidence of lethal diseases or in the associated treatment cost. The sign of an indirect effect crucially depends on health care expenditure for “new survivors” relative to their peers. The analysis yields a number of general results with respect to the impact of medical progress on the age profile of health care expenditure. For example, both compression of morbidity and expansion of morbidity are hypotheses which relate to “new survivors” such that they fail to account for the total effect of progress on age-specific expenditure.